The general objective of this research project is to identify genetic lesions involved in the pathogenesis of non-Hodgkin lymphoma (NHL) and to test their diagnostic and prognostic significance. The following specific aims will be pursued: 1. Characterization and testing of the clinico-prognostic significance of structural alterations of the BCL-6 gene. We have recently identified a novel candidate protooncogene, BCL-6, which is involved in chromosomal translocations affecting 3q27 and is rearranged in up to 45% of diffuse large cell NHL, the most significant NHL type in terms of morbidity and mortality. Based on these results we will: i) Characterize the repertoire of structural alterations (rearrangements/mutations) affecting the BCL-6 gene in NHL; ii) Test the utility of BCL-6 alterations as clinico- pathologic markers by screening a large panel of NHL and correlating the results with a number of relevant clinical parameters. 2. Molecular analysis of chromosomal translocations affecting 9pl3 and l0q24 in NHL. Alterations involving chromosomal regions 9pl3 and 10q24 are detectable in 10-15% of NHL at the cytogenetic level and may be more frequent at the molecular level. We plan to clone the regions involved in the chromosomal breakpoints, search for the involved genes and define their alterations in NHL. Once these alterations will be defined, their clinico-pathologic relevance will be determined as in Specific Aim l. 3. Identification of altered apoptosis-resistance (APR) genes in NHL. Our preliminary data indicate that a significant fraction of NHL cases contain DNA sequences which are able to cause resistance to apoptosis in a novel assay involving the transfection of total tumor DNA into MYC-transfected Rat-1 cells and induction of apoptosis by serum deprivation. We plan to characterize these sequences, identify the putative APR genes, identify the nature of the activating mutations and determine their frequency in lymphoid malignancies. Eventually, we will test the utility of these alterations as clinico-pathologic markers as in Specific Aim 1. Taken together the results of these studies should lead to further understanding of the pathogenesis of NHL and provide markers for improved diagnosis, prognosis and clinical monitoring of this heterogeneous group of neoplasms.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA044029-11
Application #
2007621
Study Section
Pathology B Study Section (PTHB)
Project Start
1989-07-15
Project End
1999-11-30
Budget Start
1996-12-01
Budget End
1997-11-30
Support Year
11
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Pathology
Type
Schools of Medicine
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Hauptschein, R S; Gaidano, G; Rao, P H et al. (2000) An apparent interlocus gene conversion-like event at a putative tumor suppressor gene locus on human chromosome 6q27 in a Burkitt's lymphoma cell line. DNA Res 7:261-72
Butler, M P; Wang, S I; Chaganti, R S et al. (1999) Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas. Genes Chromosomes Cancer 24:322-7
Pasqualucci, L; Migliazza, A; Fracchiolla, N et al. (1998) BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci U S A 95:11816-21
Hauptschein, R S; Gamberi, B; Rao, P H et al. (1998) Cloning and mapping of human chromosome 6q26-q27 deleted in B-cell non-Hodgkin lymphoma and multiple tumor types. Genomics 50:170-86
Chaganti, S R; Rao, P H; Chen, W et al. (1998) Deregulation of BCL6 in non-Hodgkin lymphoma by insertion of IGH sequences in complex translocations involving band 3q27. Genes Chromosomes Cancer 23:328-36
Chen, W; Butler, M; Rao, P H et al. (1998) The t(2;3)(q21;q27) translocation in non-Hodgkin's lymphoma displays BCL6 mutations in the 5' regulatory region and chromosomal breakpoints distant from the gene. Oncogene 17:1717-22
Chen, W; Iida, S; Louie, D C et al. (1998) Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation. Blood 91:603-7
Chaganti, S R; Chen, W; Parsa, N et al. (1998) Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. Genes Chromosomes Cancer 23:323-7
Carbone, A; Gaidano, G; Gloghini, A et al. (1997) BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression. Am J Pathol 150:155-65
Carbone, A; Gloghini, A; Gaidano, G et al. (1997) BCL-6 protein expression in human peripheral T-cell neoplasms is restricted to CD30+ anaplastic large-cell lymphomas. Blood 90:2445-50

Showing the most recent 10 out of 55 publications